157 related articles for article (PubMed ID: 31387870)
1. Effect of Size on Solid Tumor Disposition of Protein Therapeutics.
Li Z; Li Y; Chang HP; Chang HY; Guo L; Shah DK
Drug Metab Dispos; 2019 Oct; 47(10):1136-1145. PubMed ID: 31387870
[TBL] [Abstract][Full Text] [Related]
2. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
[TBL] [Abstract][Full Text] [Related]
4. Effect of the Size of Protein Therapeutics on Brain Pharmacokinetics Following Systematic Administration.
Chang HY; Wu S; Li Y; Guo L; Li Y; Shah DK
AAPS J; 2022 May; 24(3):62. PubMed ID: 35501500
[TBL] [Abstract][Full Text] [Related]
5. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
6. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.
Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK
AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
Sharma S; Li Z; Bussing D; Shah DK
Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
[TBL] [Abstract][Full Text] [Related]
8. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.
Meyer S; Nederend M; Jansen JH; Reiding KR; Jacobino SR; Meeldijk J; Bovenschen N; Wuhrer M; Valerius T; Ubink R; Boross P; Rouwendal G; Leusen JH
MAbs; 2016; 8(1):87-98. PubMed ID: 26466856
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration.
Bussing D; Li Z; Li Y; Chang HP; Chang HY; Guo L; Verma A; Shah DK
AAPS J; 2021 Nov; 23(6):116. PubMed ID: 34750690
[TBL] [Abstract][Full Text] [Related]
10. A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments.
Li Z; Yu X; Li Y; Verma A; Chang HP; Shah DK
AAPS J; 2021 May; 23(3):62. PubMed ID: 33942169
[TBL] [Abstract][Full Text] [Related]
11. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
Li Z; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
[TBL] [Abstract][Full Text] [Related]
12.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin
Quartino AL; Li H; Kirschbrown WP; Mangat R; Wada DR; Garg A; Jin JY; Lum B
Cancer Chemother Pharmacol; 2019 Feb; 83(2):329-340. PubMed ID: 30467591
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in The Mouse Eye Following Intravitreal Administration.
Bussing D; Li Y; Guo L; Verma A; Sullivan JM; Shah DK
J Pharm Sci; 2023 Aug; 112(8):2276-2284. PubMed ID: 37062415
[TBL] [Abstract][Full Text] [Related]
15. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.
Betts A; Clark T; Jasper P; Tolsma J; van der Graaf PH; Graziani EI; Rosfjord E; Sung M; Ma D; Barletta F
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):513-526. PubMed ID: 32710210
[TBL] [Abstract][Full Text] [Related]
16. A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.
Singh AP; Shah DK
J Pharm Sci; 2019 Jul; 108(7):2465-2475. PubMed ID: 30790581
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).
Singh AP; Maass KF; Betts AM; Wittrup KD; Kulkarni C; King LE; Khot A; Shah DK
AAPS J; 2016 Jul; 18(4):861-75. PubMed ID: 27029797
[TBL] [Abstract][Full Text] [Related]
18. Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies.
Nazarova L; Rafidi H; Mandikian D; Ferl GZ; Koerber JT; Davies CW; Ulufatu S; Ho J; Lau J; Yu SF; Ernst J; Sadowsky JD; Boswell CA
Mol Cancer Ther; 2020 Apr; 19(4):1052-1058. PubMed ID: 32024685
[TBL] [Abstract][Full Text] [Related]
19. Locoregional therapy with α-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice.
Li HK; Morokoshi Y; Nagatsu K; Kamada T; Hasegawa S
Cancer Sci; 2017 Aug; 108(8):1648-1656. PubMed ID: 28514062
[TBL] [Abstract][Full Text] [Related]
20. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]